Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Safety and Clinical Outcomes of an Equine-Derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States.

Richardson JS, Parrera GS, Astacio H, Sahota H, Anderson DM, Hall C, Babinchak T.

Clin Infect Dis. 2019 Jun 15. pii: ciz515. doi: 10.1093/cid/ciz515. [Epub ahead of print]

PMID:
31209461
2.

Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura.

Donga PZ, Bilir SP, Little G, Babinchak T, Munakata J.

J Med Econ. 2017 Nov;20(11):1200-1206. doi: 10.1080/13696998.2017.1370425. Epub 2017 Sep 8.

PMID:
28882075
3.

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.

Collins PW, Quon DVK, Makris M, Chowdary P, Kempton CL, Apte SJ, Ramanan MV, Hay CRM, Drobic B, Hua Y, Babinchak TJ, Gomperts ED.

Haemophilia. 2018 Jan;24(1):104-112. doi: 10.1111/hae.13324. Epub 2017 Aug 17.

4.

Methicillin-resistant Staphylococcus aureus infection epidemiology and clinical response from tigecycline soft tissue infection trials.

Puzniak LA, Quintana A, Wible M, Babinchak T, McGovern PC.

Diagn Microbiol Infect Dis. 2014 Jun;79(2):261-5. doi: 10.1016/j.diagmicrobio.2014.03.001. Epub 2014 Mar 12.

PMID:
24725736
5.

Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010.

Babinchak T, Badal R, Hoban D, Hackel M, Hawser S, Lob S, Bouchillon S.

Diagn Microbiol Infect Dis. 2013 Jul;76(3):379-81. doi: 10.1016/j.diagmicrobio.2013.02.031. Epub 2013 Mar 27.

PMID:
23541118
6.

Tigecycline: an update.

Stein GE, Babinchak T.

Diagn Microbiol Infect Dis. 2013 Apr;75(4):331-6. doi: 10.1016/j.diagmicrobio.2012.12.004. Epub 2013 Jan 26. Review.

PMID:
23357291
7.

A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections.

Matthews P, Alpert M, Rahav G, Rill D, Zito E, Gardiner D, Pedersen R, Babinchak T, McGovern PC; Tigecycline 900 cSSSI Study Group.

BMC Infect Dis. 2012 Nov 12;12:297. doi: 10.1186/1471-2334-12-297.

8.

Switch therapy in hospitalized patients with community-acquired pneumonia: tigecycline vs. levofloxacin.

Ramirez JA, Cooper AC, Wiemken T, Gardiner D, Babinchak T; 308 Study Group.

BMC Infect Dis. 2012 Jul 19;12:159. doi: 10.1186/1471-2334-12-159.

9.

Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial.

Qvist N, Warren B, Leister-Tebbe H, Zito ET, Pedersen R, McGovern PC, Babinchak T.

Surg Infect (Larchmt). 2012 Apr;13(2):102-9. doi: 10.1089/sur.2011.048. Epub 2012 Mar 22.

PMID:
22439781
10.

Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza.

Metersky ML, Masterton RG, Lode H, File TM Jr, Babinchak T.

Int J Infect Dis. 2012 May;16(5):e321-31. doi: 10.1016/j.ijid.2012.01.003. Epub 2012 Mar 2. Review.

11.

Clarification to the systematic review and meta-analysis involving tigecycline.

McGovern P, Babinchak T, Quintana A.

Antimicrob Agents Chemother. 2011 Oct;55(10):4941. doi: 10.1128/AAC.00512-11. No abstract available.

12.

Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009.

Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T.

Int J Antimicrob Agents. 2011 Mar;37(3):219-24. doi: 10.1016/j.ijantimicag.2010.10.029. Epub 2011 Jan 15.

PMID:
21239146
13.

A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections.

Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T.

Clin Microbiol Infect. 2010 Aug;16(8):1274-81. doi: 10.1111/j.1469-0691.2010.03122.x.

14.

Impact of different factors on the probability of clinical response in tigecycline-treated patients with intra-abdominal infections.

Bhavnani SM, Rubino CM, Ambrose PG, Babinchak TJ, Korth-Bradley JM, Drusano GL.

Antimicrob Agents Chemother. 2010 Mar;54(3):1207-12. doi: 10.1128/AAC.00182-09. Epub 2009 Dec 28.

15.

Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.

Gardiner D, Dukart G, Cooper A, Babinchak T.

Clin Infect Dis. 2010 Jan 15;50(2):229-38. doi: 10.1086/648720.

PMID:
20025527
16.

Exposure-response analyses of tigecycline tolerability in healthy subjects.

Passarell J, Ludwig E, Liolios K, Meagher AK, Grasela TH, Babinchak T, Ellis-Grosse EJ.

Diagn Microbiol Infect Dis. 2009 Oct;65(2):123-9. doi: 10.1016/j.diagmicrobio.2009.06.019.

PMID:
19748422
17.

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections - the European experience.

Fomin P, Koalov S, Cooper A, Babinchak T, Dartois N, De Vane N, Castaing N, Tellado J; 301 And 306 Study Groups.

J Chemother. 2008 Oct;20 Suppl 1:12-9.

PMID:
19036670
18.

Use of a clinically derived exposure-response relationship to evaluate potential tigecycline-Enterobacteriaceae susceptibility breakpoints.

Ambrose PG, Meagher AK, Passarell JA, Van Wart SA, Cirincione BB, Rubino CM, Korth-Bradley JM, Babinchak T, Ellis-Grosse E.

Diagn Microbiol Infect Dis. 2009 Jan;63(1):38-42. doi: 10.1016/j.diagmicrobio.2008.09.014.

PMID:
19073300
19.

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.

Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E; 309 Study Group.

J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i29-40. doi: 10.1093/jac/dkn249.

PMID:
18684704
20.

Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.

Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N, Gandjini H; 307 Study Group.

J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i17-28. doi: 10.1093/jac/dkn250.

PMID:
18684703
21.

Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.

Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2008 Jan;52(1):204-10. Epub 2007 Oct 22.

22.

Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.

Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG.

Antimicrob Agents Chemother. 2007 Jun;51(6):1939-45. Epub 2007 Mar 12.

23.

Mortality and gram-negative rod bacteraemia in the intensive care unit.

Gardiner DF, Scholand SJ, Babinchak T.

J Hosp Infect. 2006 Apr;62(4):453-7. Epub 2006 Feb 7.

PMID:
16455161
24.

Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates.

McAleese F, Murphy E, Babinchak T, Singh G, Said-Salim B, Kreiswirth B, Dunman P, O'Connell J, Projan SJ, Bradford PA.

Antimicrob Agents Chemother. 2005 Nov;49(11):4521-9.

25.
26.

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data.

Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E; Tigecycline 301 Study Group; Tigecycline 306 Study Group.

Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S354-67.

PMID:
16080073
27.

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam.

Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E; Tigecycline 300 cSSSI Study Group; Tigecycline 305 cSSSI Study Group.

Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S341-53.

PMID:
16080072
28.

Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals.

Desimone JA Jr, Babinchak TJ, Kaulback KR, Pomerantz RJ.

AIDS Patient Care STDS. 2003 Dec;17(12):617-22.

PMID:
14746655
29.

Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.

Ruane PJ, Parenti DM, Margolis DM, Shepp DH, Babinchak TJ, Van Kempen AS, Kauf TL, Danehower SA, Yau L, Hessenthaler SM, Goodwin D, Hernandez JE; COL30336 Study Team.

HIV Clin Trials. 2003 Jul-Aug;4(4):231-43.

PMID:
12916008
30.

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW, Zervos M, McKinsey D, Lee J, Babinchak T, Bradsher RW, Cleary JD, Cohen DM, Danziger L, Goldman M, Goodman J, Hilton E, Hyslop NE, Kett DH, Lutz J, Rubin RH, Scheld WM, Schuster M, Simmons B, Stein DK, Washburn RG, Mautner L, Chu TC, Panzer H, Rosenstein RB, Booth J; National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Clin Infect Dis. 2003 May 15;36(10):1221-8. Epub 2003 May 8.

PMID:
12746765
31.

Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.

Kulkosky J, Nunnari G, Otero M, Calarota S, Dornadula G, Zhang H, Malin A, Sullivan J, Xu Y, DeSimone J, Babinchak T, Stern J, Cavert W, Haase A, Pomerantz RJ.

J Infect Dis. 2002 Nov 15;186(10):1403-11. Epub 2002 Oct 29.

PMID:
12404155
32.

Causes of common illnesses: an overview.

Babinchak T.

J Sch Nurs. 2002 Oct;Suppl:8-11. Review. No abstract available.

PMID:
12387599
33.

Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups.

Dornadula G, Nunnari G, Vanella M, Roman J, Babinchak T, DeSimone J, Stern J, Braffman M, Zhang H, Pomerantz RJ.

J Infect Dis. 2001 Jun 1;183(11):1682-7. Epub 2001 Apr 27.

PMID:
11343220
34.

Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.

DeSimone JA, Pomerantz RJ, Babinchak TJ.

Ann Intern Med. 2000 Sep 19;133(6):447-54. Review.

PMID:
10975963
35.

Herpes simplex peritonitis: case report.

Yakulis R, Babinchak TJ.

Clin Infect Dis. 1999 Jun;28(6):1212-5.

PMID:
10451155
36.

Pyogenic vertebral osteomyelitis of the posterior elements.

Babinchak TJ, Riley DK, Rotheram EB Jr.

Clin Infect Dis. 1997 Aug;25(2):221-4. Review.

PMID:
9332515
37.

Cardiac arrhythmias associated with coadministration of azole compounds and cisapride.

Chan-Tompkins NH, Babinchak TJ.

Clin Infect Dis. 1997 Jun;24(6):1285. No abstract available.

PMID:
9195113
38.

Infectious complications of hepatic cryosurgery.

Riley DK, Babinchak TJ, Zemel R, Weaver ML, Rotheram EB.

Clin Infect Dis. 1997 May;24(5):1001-3.

PMID:
9142812
39.

Tuberculosis: yesterday, today, and tomorrow.

Riley DK, Babinchak TJ, Rotherams EB Jr.

Ann Intern Med. 1996 Feb 15;124(4):455-6. No abstract available.

PMID:
8554260
40.

Oral ciprofloxacin therapy for prosthetic valve endocarditis due to Actinobacillus actinomycetemcomitans.

Babinchak TJ.

Clin Infect Dis. 1995 Dec;21(6):1517-8. No abstract available.

PMID:
8749655
41.

Patients treated by a thoracic surgeon with HIV. A review.

Babinchak TJ, Renner C.

Chest. 1994 Sep;106(3):681-3.

PMID:
8082338
42.

In vitro activity of DNA gyrase inhibitors, singly and in combination, against Mycobacterium avium complex.

Babinchak TJ, Fass RJ.

Diagn Microbiol Infect Dis. 1992 May-Jun;15(4):367-70.

PMID:
1319302
43.

Quinolone antibacterial agents for the treatment of genitourinary tract infections.

Babinchak TJ, Fass RJ.

Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1111-6. Review.

PMID:
2695332

Supplemental Content

Loading ...
Support Center